Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

Back to Jobs

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohort Expansion study will support endpoint selection and powering for Phase 2 Top-line results expected in mid-2022 SAN DIEGO , June 15, 2021 (GLOBE

Apply Now